LA
TLSI icon

Linden Advisors’s TriSalus Life Sciences TLSI Stock Holding History

Linden Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-53,782
Closed -$535K – 583
2022
Q3 		$535K Hold
53,782
– – ﹤0.01% 413
2022
Q2 		$530K Sell
53,782
-777,021
-94% -$7.64M ﹤0.01% 444
2022
Q1 		$8.14M Buy
830,803
+100,000
+14% +$987K 0.05% 242
2021
Q4 		$7.22M Hold
730,803
– – 0.04% 229
2021
Q3 		$7.26M Hold
730,803
– – 0.04% 237
2021
Q2 		$7.09M Hold
730,803
– – 0.04% 254
2021
Q1 		$7.06M Buy
+730,803
New +$7.41M 0.05% 223

Other funds holding TLSI

MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Linden Advisors's TLSI Position: Q4 2022 in Review

Linden Advisors sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 53,782 shares — an estimated $535K sold.

Linden Advisors first reported a position in TLSI in Q1 2021 and held it in 7 quarters. The position peaked at $8.14M in Q1 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Linden Advisors reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Linden Advisors sold 53,782 TriSalus Life Sciences shares in Q4 2022, an estimated $535K.
  • Linden Advisors first reported a position in TriSalus Life Sciences in Q1 2021 and held it in 7 quarters.
  • Linden Advisors's TriSalus Life Sciences position peaked at $8.14M in Q1 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Linden Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.